Jiamao Lin

820 total citations
39 papers, 569 citations indexed

About

Jiamao Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jiamao Lin has authored 39 papers receiving a total of 569 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Jiamao Lin's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jiamao Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jiamao Lin collaborates with scholars based in China, United Kingdom and United States. Jiamao Lin's co-authors include Haiyong Wang, Chenyue Zhang, Zhenxiang Li, Chenxing Zhang, Xiaoling Shang, Haiyong Wang, Qingliang Wang, Linmao Lyu, Lijun Fang and Xinyu Song and has published in prestigious journals such as Frontiers in Immunology, European Journal of Pharmacology and BMC Cancer.

In The Last Decade

Jiamao Lin

39 papers receiving 563 citations

Peers

Countries citing papers authored by Jiamao Lin

Since Specialization

Citations

This map shows the geographic impact of Jiamao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiamao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiamao Lin more than expected).

Fields of papers citing papers by Jiamao Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiamao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiamao Lin. The network helps show where Jiamao Lin may publish in the future.

Co-authorship network of co-authors of Jiamao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Jiamao Lin. A scholar is included among the top collaborators of Jiamao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiamao Lin. Jiamao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review 2023 ·Frontiers in Oncology ·Zhiqin Zhang, Jiamao Lin, (unknown), Yang Li	1
2	Whole exome sequencing in Chinese mucinous pulmonary adenocarcinoma uncovers specific genetic variations different from lung adenocarcinoma 2022 ·Frontiers in Oncology ·Chenyue Zhang, Kai Wang, Wenjie Liu, Jiamao Lin, Zhenxiang Li, Hui Wang, (unknown), Yanhua Chen, Shuangxiu Wu, Airong Yang, Jiayan Wu, Haiyong Wang	1
3	Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma 2022 ·International Journal of General Medicine ·Chenyue Zhang, Zhenxiang Li, Yanxiang Zhang, (unknown), (unknown), Jiamao Lin, Cuicui Liu, Xiaohui Wang, Haiyong Wang	8
4	Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab 2021 ·Lung Cancer ·Xiaoling Shang, Zhenxiang Li, (unknown), (unknown), Jiamao Lin, Haiyong Wang	19
5	A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab 2021 ·Frontiers in Immunology ·Jiamao Lin, Xiaohui Wang, Chenyue Zhang, (unknown), (unknown), Haiyong Wang	3
6	Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma 2021 ·Frontiers in Oncology ·Lijuan Zhang, Tian Meng, Jiamao Lin, Jianbo Zhang, Haiyong Wang, Zhenxiang Li	2
7	Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC 2021 ·International Journal of General Medicine ·Chenyue Zhang, Xiaoling Shang, (unknown), Zhenxiang Li, Jiamao Lin, (unknown), Haiyong Wang	3
8	CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma 2020 ·International Immunopharmacology ·Xiaoling Shang, Jia Li, Hui Wang, Zhenxiang Li, Jiamao Lin, Dawei Chen, Haiyong Wang	16
9	Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study 2020 ·JTO Clinical and Research Reports ·Chenxing Zhang, Chenyue Zhang, Jiamao Lin, Zhenxiang Li, Haiyong Wang	12
10	A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study 2020 ·Journal of Oncology ·Xiaoling Shang, (unknown), Jiamao Lin, (unknown), (unknown), (unknown), Haiyong Wang	9
11	Comprehensive analysis of multiple parameters associated with tumor immune microenvironment in ARID1A mutant cancers 2020 ·Future Oncology ·Zhenxiang Li, Jiamao Lin, Lijuan Zhang, Jingchao Li, (unknown), (unknown), Haiyong Wang	8
12	A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC 2019 ·BMC Cancer ·Xiaoling Shang, Jia Liu, (unknown), Jiamao Lin, Haiyong Wang	13
13	Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress 2019 ·European Journal of Pharmacology ·Jiamao Lin, Lijun Fang, (unknown), Zhenxiang Li, Linmao Lyu, Haiyong Wang, Jun Xiao	68
14	Surgery as a Potential Treatment Option for Patients With Stage III Small-Cell Lung Cancer: A Propensity Score Matching Analysis 2019 ·Frontiers in Oncology ·Chenyue Zhang, Cheng Li, Xiaoling Shang, Jiamao Lin, Haiyong Wang	12
15	Radiotherapy may improve survival of ES‑SCLC with distant metastasis only for patients with one metastatic site: A population‑based study 2019 ·Oncology Letters ·Xiaoling Shang, Jiamao Lin, Zhenxiang Li, Haiyong Wang	8
16	Circular RNA Hsa_Circ_0091579 Serves as a Diagnostic and Prognostic Marker for Hepatocellular Carcinoma 2018 ·Cellular Physiology and Biochemistry ·Chenxing Zhang, Chenyue Zhang, Jiamao Lin, Haiyong Wang	38
17	PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study 2018 ·Cancer Management and Research ·Xiaoling Shang, (unknown), Jiamao Lin, Haiyong Wang, Zhehai Wang	6
18	Screening differential circular RNA expression profiles reveal that hsa_circ_0128298 is a biomarker in the diagnosis and prognosis of hepatocellular carcinoma 2018 ·Cancer Management and Research ·Dawei Chen, Chenyue Zhang, Jiamao Lin, Xinyu Song, Haiyong Wang	48
19	The Prognostic Analysis of Different Metastatic Patterns Extensive-Stage Small-Cell Lung Cancer Patients: A Large Population-Based Study 2018 ·Future Oncology ·(unknown), Haiyong Wang, Zhenxiang Li, Jiamao Lin, Jinming Yu	37
20	Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer 2017 ·Cell Proliferation ·Wenyu Hu, Haiyan Wei, Keming Li, Pei Li, Jiamao Lin, Rui Feng	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact